ライフサイエンスコーパス: granulomatous disease

1 es, including splenomegaly, hepatomegaly, or granulomatous disease.

2 olunteers with that in patients with chronic granulomatous disease.

3 edictor of survival in patients with chronic granulomatous disease.

4 linked to survival in patients with chronic granulomatous disease.

5 h X-linked (NOX2) or autosomal (p47) chronic granulomatous disease.

6 EROS mutations are a novel cause of chronic granulomatous disease.

7 primary immunodeficiency other than chronic granulomatous disease.

8 evere combined immune deficiency and chronic granulomatous disease.

9 -two percent practice in an area endemic for granulomatous disease.

10 Sarcoidosis is a heterogeneous multisystem granulomatous disease.

11 ciation of autoimmune disorders with chronic granulomatous disease.

12 transplantation, advanced AIDS, and chronic granulomatous disease.

13 ociation of autoimmune diseases with chronic granulomatous disease.

14 from eosinophils from a patient with chronic granulomatous disease.

15 the oxidative burst in patients with chronic granulomatous disease.

16 rophils from a patient with X-linked chronic granulomatous disease.

17 ifungal agents in the prophylaxis of chronic granulomatous disease.

18 proach in the molecular treatment of chronic granulomatous disease.

19 iency, Wiskott-Aldrich syndrome, and chronic granulomatous disease.

20 against serious fungal infections in chronic granulomatous disease.

21 derived from patients with X-linked chronic granulomatous disease.

22 s known to have unusual virulence in chronic granulomatous disease.

23 herapy protocols being developed for chronic granulomatous disease.

24 X-linked gene CYBB, thereby causing chronic granulomatous disease.

25 of patients with cystic fibrosis and chronic granulomatous disease.

26 fering from cystic fibrosis (CF) and chronic granulomatous disease.

27 x)) gives rise to the known types of chronic granulomatous disease.

28 have been detected in patients with chronic granulomatous disease.

29 reas the late response is a typical Th1-type granulomatous disease.

30 s with disease and were molecular markers of granulomatous disease.

31 und to be associated with silicosis, another granulomatous disease.

32 mulated monocytes from patients with chronic granulomatous disease.

33 and fungal infections, resulting in chronic granulomatous disease.

34 Necrobiosis lipoidica (NL) is a rare granulomatous disease.

35 , and the exclusion of alternative causes of granulomatous disease.

36 ity, lymphoid proliferation, malignancy, and granulomatous disease.

37 hagocyte functional defects, such as chronic granulomatous disease.

38 ive ROS production machinery develop chronic granulomatous disease.

39 sed by a Phellinus sp. in a boy with chronic granulomatous disease.

40 ficacious in high-risk patients with chronic granulomatous disease.

41 n-1 deficiency, CARD9 deficiency, or chronic granulomatous disease.

42 ctions, such as the genetic disorder chronic granulomatous disease.

43 th other lung diseases, including infectious granulomatous diseases.

44 shared mechanisms for TGF-beta1 in these two granulomatous diseases.

45 r the rational design of immunotherapies for granulomatous diseases.

46 and questions about macrophage function and granulomatous diseases.

47 mmatory disease, 15.4%; malabsorption, 5.9%; granulomatous disease, 9.7%; liver diseases and hepatiti

48 ic defect causing p47-phox-deficient chronic granulomatous disease (A47 degrees CGD) is a GT deletion

49 In the genetic disorder chronic granulomatous disease, absent oxidase function is associ

50 In chronic granulomatous disease allogeneic haemopoietic stem-cell

51 Chronic granulomatous disease, an inherited disorder of the NADP

52 leotide phosphate oxidase defects in chronic granulomatous disease and beta2 integrin defects in leuk

53 this complex have been implicated in chronic granulomatous disease and Crohn's disease, highlighting

54 idity and mortality in patients with chronic granulomatous disease and cystic fibrosis.

55 therapy in genetic disorders such as chronic granulomatous disease and infectious diseases such as le

56 ases of rhinosporidiosis, which is a chronic granulomatous disease and is endemic in India and Sri La

57 Chronic granulomatous disease and leukocyte adhesion deficiency

58 s in development of gene therapy for chronic granulomatous disease and leukocyte adhesion deficiency-

59 articularly beneficial in areas with endemic granulomatous disease and may improve clinical managemen

60 Patients with chronic granulomatous disease and modest residual production of

61 abscess formation in a patient with chronic granulomatous disease and review the literature on Phaeo

62 reased susceptibility to chronic infections, granulomatous disease and the lymphoproliferative predis

63 ted for other forms of PID including chronic granulomatous disease and Wiskott-Aldrich syndrome.

64 Location in an area endemic for granulomatous disease and years of experience also influ

65 tage of ABC-like cells in patients with lung granulomatous diseases and decrease in treated patients

66 ed severe combined immunodeficiency, chronic granulomatous disease, and other diseases.

67 These results have implications for granulomatous diseases, and conditions such as atheroscl

68 Sarcoidosis is a systemic granulomatous disease associated with local epithelioid

69 nfection models, idiopathic IBD, and chronic granulomatous disease-associated IBD undergo extensive t

70 he frequency of fungal infections in chronic granulomatous disease, but monitoring for long-term toxi

71 acoronavirus, resulting in a lethal systemic granulomatous disease called feline infectious peritonit

72 Patients with chronic granulomatous disease can develop chronic granulomas in

73 ways of host immune cells in tuberculosis, a granulomatous disease caused by the intracellular pathog

74 ron-gamma is important for the expression of granulomatous diseases caused by infectious agents; howe

75 diates (ROIs) is the major defect in chronic granulomatous disease, causing recurrent infections and

76 unocompromising condition, including chronic granulomatous disease (CGD) (n=4), diabetes mellitus (DM

77 The rarer PID patients without chronic granulomatous disease (CGD) achieved an OS at 3 years of

78 common cause of autosomal recessive chronic granulomatous disease (CGD) and is considered to be asso

79 s involved in the pathophysiology of chronic granulomatous disease (CGD) and sepsis.

80 circulating B cells in patients with chronic granulomatous disease (CGD) and those with HIV infection

81 a phenotype similar to that of human chronic granulomatous disease (CGD) and, thus, is an excellent m

82 Liver abscesses in chronic granulomatous disease (CGD) are typically difficult to t

83 in p47-phox-deficient (A47 degrees ) chronic granulomatous disease (CGD) as a result of the insertion

84 Chronic granulomatous disease (CGD) can be cured by allogeneic h

85 Chronic granulomatous disease (CGD) can result from any of four

86 fective neutrophils in patients with chronic granulomatous disease (CGD) cause susceptibility to extr

87 from a registry of 368 patients with chronic granulomatous disease (CGD) documenta shift in the most

88 ed in human patients who suffer from chronic granulomatous disease (CGD) due to defective NADPH oxida

89 Patients with chronic granulomatous disease (CGD) exhibit deficient generation

90 Patients with chronic granulomatous disease (CGD) experience immunodeficiency

91 leukocytes (PMN) from patients with chronic granulomatous disease (CGD) fail to produce microbicidal

92 educed in the blood of patients with chronic granulomatous disease (CGD) for reasons and consequences

93 Mice with X-linked chronic granulomatous disease (CGD) generated by targeted disrup

94 Although prognosis of Chronic Granulomatous Disease (CGD) has greatly improved, few st

95 Patients with chronic granulomatous disease (CGD) have a mutated NADPH complex

96 t described the clinical features of chronic granulomatous disease (CGD) in 1959.

97 ears of age) often resembles that of chronic granulomatous disease (CGD) in extent and features of co

98 Chronic granulomatous disease (CGD) is a genetic disorder of NAD

99 Chronic granulomatous disease (CGD) is a group of inherited diso

100 Chronic granulomatous disease (CGD) is a hereditary disorder of

101 Chronic granulomatous disease (CGD) is a primary immune deficien

102 Chronic granulomatous disease (CGD) is a primary immune deficien

103 Chronic granulomatous disease (CGD) is a primary immunodeficienc

104 Chronic granulomatous disease (CGD) is a primary immunodeficienc

105 Chronic granulomatous disease (CGD) is a primary immunodeficienc

106 Chronic granulomatous disease (CGD) is a primary immunodeficienc

107 Chronic granulomatous disease (CGD) is a primary immunodeficienc

108 Chronic granulomatous disease (CGD) is a primary immunodeficienc

109 Chronic granulomatous disease (CGD) is a rare congenital disorde

110 Chronic granulomatous disease (CGD) is a rare genetic disorder i

111 Chronic granulomatous disease (CGD) is a rare genetic disorder,

112 Chronic granulomatous disease (CGD) is a rare inherited disorder

113 Chronic granulomatous disease (CGD) is a rare inherited disorder

114 Chronic granulomatous disease (CGD) is a rare inherited disorder

115 Chronic granulomatous disease (CGD) is a rare phagocytic disorde

116 Chronic granulomatous disease (CGD) is a rare primary immunodefi

117 Chronic granulomatous disease (CGD) is a severe monogenic immuno

118 Chronic granulomatous disease (CGD) is an inborn error of immuni

119 Chronic granulomatous disease (CGD) is an inborn error of immuni

120 Chronic granulomatous disease (CGD) is an inborn error of immuni

121 Chronic granulomatous disease (CGD) is an inherited deficiency o

122 Chronic granulomatous disease (CGD) is an inherited disease caus

123 Chronic granulomatous disease (CGD) is an inherited disorder cha

124 Chronic granulomatous disease (CGD) is an inherited disorder of

125 Chronic granulomatous disease (CGD) is an inherited disorder of

126 Chronic granulomatous disease (CGD) is an inherited hematologic

127 Chronic granulomatous disease (CGD) is an inherited immune defic

128 Chronic granulomatous disease (CGD) is an inherited immunodefici

129 aspergillosis (IA) in patients with chronic granulomatous disease (CGD) is Aspergillus fumigatus fol

130 Chronic granulomatous disease (CGD) is associated with significa

131 Chronic granulomatous disease (CGD) is caused by defects in any

132 Chronic granulomatous disease (CGD) is characterized by overexub

133 Chronic granulomatous disease (CGD) is characterized by recurren

134 Chronic granulomatous disease (CGD) is characterized by severe r

135 Chronic granulomatous disease (CGD) is due to defective nicotina

136 Immunodeficiency in chronic granulomatous disease (CGD) is well characterized.

137 NADPH oxidase 2 (Nox2)-deficient chronic granulomatous disease (CGD) mice that lack the gp91(phox

138 rmal volunteers and in patients with chronic granulomatous disease (CGD) or adenosine deaminase (ADA)

139 inhibited oxidase, or isolated from chronic granulomatous disease (CGD) patients and mice, formed mo

140 Chronic granulomatous disease (CGD) patients are susceptible to

141 Chronic granulomatous disease (CGD) patients have recurrent life

142 hosphate (NADPH) oxidase predisposes chronic granulomatous disease (CGD) patients to infection, and a

143 ide (NADPH) oxidase in patients with chronic granulomatous disease (CGD) results in susceptibility to

144 s and neutrophils from patients with chronic granulomatous disease (CGD) that are completely deficien

145 serious infections in patients with chronic granulomatous disease (CGD) through an unknown mechanism

146 m-negative pathogen in patients with chronic granulomatous disease (CGD), a deficiency in the phagocy

147 B cell compartment in patients with chronic granulomatous disease (CGD), a disorder of phagocyte fun

148 prolonged neutropenia or in cases of chronic granulomatous disease (CGD), a primary immunodeficiency

149 bacterium that infects patients with chronic granulomatous disease (CGD), a primary immunodeficiency

150 hate oxidase 2 (NOX2) function cause chronic granulomatous disease (CGD), a primary immunodeficiency

151 r threat for patients suffering from chronic granulomatous disease (CGD), a primary immunodeficiency

152 her p22(phox) or gp91(phox) leads to chronic granulomatous disease (CGD), a severe immune disorder ch

153 h of which are mouse models of human chronic granulomatous disease (CGD), also lack LTP.

154 Chronic granulomatous disease (CGD), an immunodeficiency with re

155 s in development of gene therapy for chronic granulomatous disease (CGD), an inherited defect in leuk

156 stem cell transplants, patients with chronic granulomatous disease (CGD), and others.

157 ing mutations in this enzyme lead to chronic granulomatous disease (CGD), associated with increased s

158 Genetic defects in NOX2 result in chronic granulomatous disease (CGD), associated with microbial i

159 (HSCT) is a successful treatment for chronic granulomatous disease (CGD), but the safety and efficacy

160 and often the first manifestation of chronic granulomatous disease (CGD), caused by inborn defects in

161 c defects in NADPH oxidase result in chronic granulomatous disease (CGD), characterized by recurrent

162 In chronic granulomatous disease (CGD), defective phagocytic nicoti

163 ox), have been described in cases of chronic granulomatous disease (CGD), defining their essential ro

164 ) and lungs of A. fumigatus-infected chronic granulomatous disease (CGD), hydrocortisone-treated, and

165 dase complex 2 (NOX2) deficiency, or chronic granulomatous disease (CGD), is an inborn error of immun

166 s from six individuals with X-linked chronic granulomatous disease (CGD), p47phox and p67phox accumul

167 atory burst, ie, from a patient with chronic granulomatous disease (CGD), was strongly inhibited by c

168 red to as NOX2), are associated with chronic granulomatous disease (CGD), which is characterized by r

169 Mutations in gp91(phox) result in chronic granulomatous disease (CGD), which is diagnosed by use o

170 n emerging pathogen in patients with chronic granulomatous disease (CGD).

171 people with cystic fibrosis (CF) and chronic granulomatous disease (CGD).

172 ls with the primary immunodeficiency chronic granulomatous disease (CGD).

173 basis for the human immunodeficiency chronic granulomatous disease (CGD).

174 covered, leading to the diagnosis of chronic granulomatous disease (CGD).

175 is the site of mutations in X-linked chronic granulomatous disease (CGD).

176 nses and exaggerated inflammation in chronic granulomatous disease (CGD).

177 Wiskott-Aldrich syndrome (WAS), and chronic granulomatous disease (CGD).

178 atients with cystic fibrosis (CF) or chronic granulomatous disease (CGD).

179 s is a major threat to patients with chronic granulomatous disease (CGD).

180 has been isolated from patients with chronic granulomatous disease (CGD).

181 Genetic defects in NADPH oxidase (chronic granulomatous disease [CGD]) and corticosteroid-induced

182 nt, and respiratory burst-deficient (chronic granulomatous disease [CGD]) neutrophils killed Escheric

183 Destructive midline granulomatous disease characterized by necrotizing granu

184 tations in the NADPH oxidase lead to chronic granulomatous disease, characterized by severe infection

185 ncies in the oxidative burst seen in chronic granulomatous disease, could lead to pathologic inflamma

186 experience, location in a region endemic for granulomatous disease, country, and practice type were a

187 h Duchenne muscular dystrophy (DMD), chronic granulomatous disease (CYBB), retinitis pigmentosa (RPGR

188 A 28-year-old man with chronic granulomatous disease developed worsening respiratory st

189 G mutations associated with autoimmunity and granulomatous disease did not have altered overall diver

190 ion at the RP3 locus, in addition to chronic granulomatous disease, Duchenne muscular dystrophy (DMD)

191 Granulomatous disease following exposure to Mycobacteriu

192 Sarcoidosis is a chronic granulomatous disease for which there are limited therap

193 ss and death among 287 patients with chronic granulomatous disease from 244 kindreds.

194 A mouse model for chronic granulomatous disease has been developed and promises to

195 Chest imaging was consistent with granulomatous disease in 46.7%.

196 virus (FIPV), which leads to lethal systemic granulomatous disease in cats.

197 tibility factors associated with more severe granulomatous disease in sarcoidosis and CBD.

198 ximately 30 degrees C, so we sought to model granulomatous disease in the ectothermic zebrafish.

199 gene therapy correction of X-linked chronic granulomatous disease in two adult patients was reported

200 arthritis and uveitis in general as well as granulomatous diseases in particular.

201 neumonitis (occupational burden, 19%); other granulomatous diseases, including sarcoidosis (occupatio

202 trophils isolated from patients with chronic granulomatous disease incubated with a caspase inhibitor

203 Chronic granulomatous disease is a rare disorder in which the ph

204 Chronic granulomatous disease is a rare inherited disorder cause

205 Chronic granulomatous disease is a rare inherited primary immuno

206 Chronic granulomatous disease is an inherited immune deficiency

207 Chronic granulomatous disease is caused by missense, nonsense, f

208 Chronic granulomatous disease is the manifestation of genetic de

209 itially conceived as a familial inflammatory granulomatous disease limited to the triad of synovitis,

210 -like cell percentages in patients with lung granulomatous diseases.Methods: Peripheral blood and BAL

211 tween 2008 and 2018 for IEIs such as chronic granulomatous disease (n = 20) and various combined immu

212 However, chronic granulomatous disease neutrophils, which do not produce

213 idosis is a component of an often multiorgan granulomatous disease of still uncertain cause.

214 Sarcoidosis is an inflammatory granulomatous disease of unknown cause that affects an e

215 Sarcoidosis is a complex systemic granulomatous disease of unknown etiology characterized

216 Sarcoidosis is a multisystem granulomatous disease of unknown etiology characterized

217 Sarcoidosis is a multisystemic granulomatous disease of unknown etiology that predomina

218 Sarcoidosis is a systemic granulomatous disease of unknown etiology that primarily

219 Sarcoidosis is a multisystem granulomatous disease of unknown etiology that primarily

220 Sarcoidosis is a systemic granulomatous disease of unknown etiology with significa

221 Sarcoidosis is a relatively common systemic granulomatous disease of unknown etiology.

222 Sarcoidosis is a chronic granulomatous disease of unknown etiology.

223 Sarcoidosis is a systemic granulomatous disease of unknown etiology.

224 linical course and pattern of sarcoidosis, a granulomatous disease of unknown origin.

225 gic alveolitis and pulmonary sarcoidosis are granulomatous diseases of the lung for which clinical pr

226 such as Wiskott-Aldrich syndrome and chronic granulomatous disease, offering curative engraftment wit

227 romised patients as well as in patients with granulomatous disease or cystic fibrosis.

228 ox), p47(phox), p67(phox) (autosomal chronic granulomatous disease), or gp91(phox) (X-linked chronic

229 bronchiectasis, autoimmunity, other cancers, granulomatous disease, or previous splenectomy.

230 h compromise p40(phox) function in a chronic granulomatous disease patient, also perturbed class II A

231 fect on endothelial function in NOX2-chronic granulomatous disease patients (-0.9; 95% confidence int

232 d dilatation was not observed in p47-chronic granulomatous disease patients (-1.5%; 95% confidence in

233 Neutrophils from chronic granulomatous disease patients and Lyn -/- mice no longe

234 rrents in granulocytes from X-linked chronic granulomatous disease patients lacking gp91(phox) (X-CGD

235 ed Mo-DC differentiation observed in chronic granulomatous disease patients lacking p22phox.

236 rmally activated in neutrophils from chronic granulomatous disease patients that lack cytochrome b558

237 The response to IR in chronic granulomatous disease patients was compared with that in

238 r NSCLC, secondary pulmonary malignancy, and granulomatous disease patients were 85%, 77%, 73%, and 8

239 Additionally, neutrophils from chronic granulomatous disease patients, carrying mutations in th

240 promise antifungal immune control in chronic granulomatous disease patients.

241 While sarcoidosis is a chronic granulomatous disease presumably reflecting an exaggerat

242 y subjects, those from patients with chronic granulomatous disease produce larger swarms against Cand

243 linicopathological presentation of pulmonary granulomatous disease, rats immunized with intravenous (

244 ith the p47(phox) deficiency form of chronic granulomatous disease received intravenous infusions of

245 a feasible option for patients with chronic granulomatous disease, recurrent life-threatening infect

246 in persons with cystic fibrosis and chronic granulomatous disease, represents one such group where n

247 Treatment of tuberculosis, a complex granulomatous disease, requires long-term multidrug ther

248 gene, whose monoallelic loss causes chronic granulomatous disease, resulted in the desired increase

249 ts and patients with the unrelated pulmonary granulomatous diseases sarcoidosis and berylliosis the s

250 the phagocyte NADPH oxidase complex (chronic granulomatous disease), severe congenital neutropenia (S

251 ntal data and description of a novel chronic granulomatous disease subtype (p40(phox)-deficiency) imp

252 ovel cytokine that is expressed in pulmonary granulomatous disease such as sarcoidosis and tuberculos

253 Additional causes of hypercalcemia include granulomatous disease such as sarcoidosis, endocrinopath

254 osus, Sjogren syndrome or Behcet disease and granulomatous diseases such as sarcoidosis.

255 hic macrophages constitutes the basis of all granulomatous diseases, such as tuberculosis or sarcoido

256 gene therapy for immunodeficiencies, chronic granulomatous disease, suicide gene therapy for graft-ve

257 Sarcoidosis is a multiorgan granulomatous disease that lacks diagnostic biomarkers a

258 eryllium (Be) disease (CBD) is a multisystem granulomatous disease that primarily affects the lung, a

259 Sarcoidosis is a granulomatous disease that primarily affects the lungs a

260 In vivo, MAC manifests as a disseminated granulomatous disease that produces a massive inflammato

261 Mice with chronic granulomatous disease that were infected with B. multivo

262 (phox-/-)) mice are a model of human chronic granulomatous disease; these mice are prone to develop s

263 SCID), Wiskott-Aldrich syndrome, and chronic granulomatous disease through retrospective, prospective

264 atients with sarcoidosis and non-sarcoidosis granulomatous disease to identify upregulation of a stro

265 nd the susceptibility of humans with chronic granulomatous disease to mycobacterial infection.

266 five children and five adults, with chronic granulomatous disease underwent peripheral-blood stem-ce

267 Survival of patients with chronic granulomatous disease was strongly associated with resid

268 ranswells and cells of patients with chronic granulomatous disease, we show that this downregulation

269 Patients aged 0-40 years with chronic granulomatous disease were assessed and enrolled at the

270 ied, while three patients (33%) with chronic granulomatous disease were cured following hematopoietic

271 n age 12.7 years; IQR 6.8-17.3) with chronic granulomatous disease were enrolled from June 15, 2003,

272 us disease), or gp91(phox) (X-linked chronic granulomatous disease), which result in variable product

273 OS) because cells from patients with chronic granulomatous disease, which are defective in ROS produc

274 nd in neutrophils from patients with chronic granulomatous disease, which lack NADPH oxidase.

275 nnate antifungal immunity, including chronic granulomatous disease, which results from inherited defi

276 as also observed in individuals with chronic granulomatous disease, who lack NADPH oxidase activity b

277 ts with the NADPH oxidase deficiency chronic granulomatous disease, who require antibiotic and antimy

278 age quiescence and prevents mTORC1-dependent granulomatous disease with clinical implications for sar

279 The treatment of chronic granulomatous disease with conventional allogeneic hemat

280 efects in oxidase function result in chronic granulomatous disease with hallmark recurrent microbial

281 Rationale: Chronic sarcoidosis is a complex granulomatous disease with limited treatment options tha

282 6PD deficiency can be a phenocopy of chronic granulomatous disease with regard to the cellular and cl

283 Mice with chronic granulomatous disease (X-CGD mice) generated by mutating

284 established murine model of X-linked chronic granulomatous disease (X-CGD) created by homologous reco

285 used in a clinical trial of X-linked chronic granulomatous disease (X-CGD) gene therapy to achieve tr

286 em cells from patients with X-linked chronic granulomatous disease (X-CGD) give rise to X-CGD-phenoty

287 entivector gene therapy for X-linked chronic granulomatous disease (X-CGD) has proven to be a viable

288 reviously demonstrated that X-linked chronic granulomatous disease (X-CGD) mice develop exaggerated i

289 nditioning of wild-type and X-linked chronic granulomatous disease (X-CGD) mice.

290 burst (phagocyte oxidase)-deficient chronic granulomatous disease (X-CGD) mice.

291 The X-linked form of chronic granulomatous disease (X-CGD) results from mutations in

292 model, because in mice with X-linked chronic granulomatous disease (X-CGD) that lack oxidase subunits

293 rst oxidase cytochrome b-558, mimics chronic granulomatous disease (X-CGD) to study the role of oxyge

294 (iPSCs) from a patient with X-linked chronic granulomatous disease (X-CGD), a defect of neutrophil mi

295 The X-linked form of chronic granulomatous disease (X-CGD), an inherited deficiency o

296 In HSPCs from patients with X-linked chronic granulomatous disease (X-CGD), caused by mutations in th

297 of which cause the X-linked form of chronic granulomatous disease (X-CGD).

298 t in patients and mice with X-linked chronic granulomatous disease (X-CGD).

299 st-deficient gp91(phox)-/- (X-linked chronic granulomatous disease [X-CGD]) mice and inducible nitric

300 PMNs from individuals with X-linked chronic granulomatous disease (XCGD) do not produce ROS, thereby